Delving into the Latest Updates on Chlorotrianisene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Chloortrianisestrol, Chlorestrolo, Chlorotrianisene (INN)

+ [8]

Target

ER

Action

agonists

Mechanism

ERs agonists(Estrogen receptors agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

HypogonadismProstatic HyperplasiaUterine Hemorrhage

Inactive Indication

Hepatocellular Carcinoma

Originator Organization

Suzhou First Pharmaceutical Co., Ltd.

Active Organization

Suzhou First Pharmaceutical Co., Ltd.

Inactive Organization

Shenzhen SiBiono GeneTech Co. Ltd.Sanofi-Aventis, Inc.Banner Pharmacaps BV

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1984),

HypogonadismProstatic HyperplasiaUterine Hemorrhage

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H21ClO3

InChIKeyBFPSDSIWYFKGBC-UHFFFAOYSA-N

CAS Registry569-57-3

Author: Takahashi, Hirokazu ; Danpanichkul, Pojsakorn ; Nah, Benjamin ; Kow, Alfred Wei Chieh ; Law, Jia Hao ; Ng, Cheng Han ; Tan, Claire Shiying ; Yu, Zhenning ; Tan, En Ying ; Seko, Yuya ; Lim, Mei Chin ; Kumar, Rahul ; Law, Michelle ; Tan, Darren Jun Hao ; Cho, Elina En Li ; Soon, Gwyneth Shook Ting ; Yong, Jie Ning ; Morishita, Asahiro ; Huang, Daniel Q ; Nakamura, Toru ; Chirapongsathorn, Sakkarin

BACKGROUNDMajor society guidelines recommend transarterial chemoembolization (TACE) as the standard of care for intermediate-stage hepatocellular carcinoma (HCC) patients. However, predicting treatment response remains challenging.AIMSAs artificial intelligence (AI) may predict therapeutic responses, this systematic review aims to assess the performance and effectiveness of radiomics and AI-based models in predicting TACE outcomes in patients with HCC.METHODSA systemic search was conducted on Medline and Embase databases from inception to 7th April 2024. Included studies generated a predictive model for TACE response and evaluated its performance by area under the curve (AUC), specificity, or sensitivity analysis. Systematic reviews, meta-analyses, case series and reports, pediatric, and animal studies were excluded. Secondary search of references of included articles ensured comprehensiveness.RESULTS64 articles, with 13,412 TACE-treated patients, were included. AI in pre-treatment CT scans provided value in predicting the efficacy of TACE in HCC treatment. A positive association was observed for AI in pre-treatment MRI scans. Models incorporating radiomics had numerically better performance than those incorporating manual measured radiological variables. 39 studies demonstrated that combined predictive models had numerically better performance than models based solely on imaging or non-imaging features.CONCLUSIONA combined predictive model incorporating clinical features, laboratory investigations, and radiological characteristics may effectively predict response to TACE treatment for HCC.

01 Jan 2025·The Lancet

TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma

Article

Author: Geier, Andreas ; Reiter, Florian P

01 Dec 2024·Asian Journal of Surgery

Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy

Article

Author: Gao, Zhen-Yu ; Wang, Kai-Di ; Shen, Guo-Liang ; Liang, Lei ; Huang, Xiao-Kun ; Ye, Tai-Wei ; Lu, Wen-Feng ; Liu, Si-Yu ; Liu, Jun-Wei ; Du, Cheng-Fei ; Zhang, Cheng-Wu ; Xu, Zhu-Ding ; Huang, Dong-Sheng ; Dai, Mu-Gen

BACKGROUND AND AIMSThe prognosis of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy is unsatisfactory, especially for those with microvascular invasion (MVI). This study aimed to determine the impact of adjuvant transcatheter arterial chemoembolization (TACE) and Lenvatinib on the prognosis of patients with HCC and MVI after hepatectomy.METHODSPatients diagnosed with HCC and MVI were reviewed, and stratified into four groups according to adjuvant TACE and/or Lenvatinib. Multivariate Cox regression analyses are used to determine independent risk factors.RESULTS346 patients were included, and divided into four groups (Group I, TACE+ Lenvatinib; Group II, Lenvatinib; Group III, TACE; Group IV, without adjuvant therapy). Multivariable analysis showed that compared to Group IV, Group I had the best effect on improving the overall survival (OS, HR 0.321, 95%CI 0.099-0.406, P = 0.001) and recurrence-free survival (RFS, HR 0.319, 95%CI 0.129-0.372, P = 0.001). Additionally, compared with Group II or Group III, Group I also can significantly improve the OS and RFS. There is no significant difference between Group II and Group III in OS and RFS.CONCLUSIONThe combination of TACE and Lenvatinib should be considered for anti-recurrence therapy for patients with HCC and MVI after hepatectomy.

100 Deals associated with Chlorotrianisene

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00269	Chlorotrianisene	G03CA06	DB00269

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypogonadism	China	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984
Prostatic Hyperplasia	China	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984
Uterine Hemorrhage	China	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 1	China	Shenzhen SiBiono GeneTech Co. Ltd.	01 Jul 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_IO2023	Not Applicable	Advanced Hepatocellular Carcinoma	73	Tislelizumab plus TKIs	(kduxtvgukf) = yuwmqjjqxi hubszadzdb (nnprbufcop ) View more	-	07 Dec 2023
				Tislelizumab plus TKIs plus TACE	(rkckyqahuh) = rigcmkjwad urumdmnkch (tcbgbgluil ) View more
113/INT/2021 (ESMO_GI2023)	Not Applicable	Second line	1,381	Lenvatinib	(qvrsjhpvim) = zdhmqyknyi skyknbbzfe (rvgrrezlmj ) View more	Positive	01 Jul 2023
				Atezolizumab plus bevacizumab	(qvrsjhpvim) = locihgobtb skyknbbzfe (rvgrrezlmj )
ASCO2023	Not Applicable	Unresectable Hepatocellular Carcinoma First line \| Second line	34	Donafenib+TACE+anti-PD1 antibody	(ndvupmjnjd) = Treatment-related adverse events (TRAE) were reported by 30 patients (88.2%), of which 7 patients (20.6%) had grade 3 TRAE. No grade 4 or 5 TRAE was reported. tagmzyygow (ejyfymalhj )	Positive	31 May 2023
ASCO2023	Not Applicable	Advanced Hepatocellular Carcinoma Second line	43	TACE+Regorafenib	lbsutogwdm(vggpojfttv) = 16.28% djroasjbbn (zdlloyeoat ) View more	Positive	31 May 2023
ASCO 12023 \| ASCO 22023 Manual	Not Applicable	Advanced Hepatocellular Carcinoma Second line	94	Regorafenib	(zfzqaczxej) = vvnkzjmvfj gnkrxhfffm (syndietdzy, 0.45 - 7.95)	Positive	26 May 2023
				PD-1 inhibitors+TACE+Regorafenib	(zfzqaczxej) = inlwigfssm gnkrxhfffm (syndietdzy, 7.09 - 10.32)
ChiCTR1800018621 (ESMO_ASIA2022) Manual	Phase 4	Hepatocellular Carcinoma	178	apatinib+TACE	(rjtejvphyq) = fgnuglmbgo elenyzmvpn (yvcqdzjvsw, 4.53 - 10.15) View more	Positive	03 Dec 2022
				TACE	(rjtejvphyq) = vwmxcpukmj elenyzmvpn (yvcqdzjvsw, 2.83 - 4.90) View more
Pubmed Manual	Not Applicable	Hepatocellular Carcinoma First line \| Neoadjuvant	51	TACE+Lenvatinib+Toripalimab	vjdcdijfaa(oscmlpsdbl) = petfgeajwe kxwnpyntlq (tmxliyryza ) View more	Positive	02 Sep 2022
				TACE+Lenvatinib	vjdcdijfaa(oscmlpsdbl) = qrzqzvmsgs kxwnpyntlq (tmxliyryza ) View more
Pubmed \| Front Oncol Manual	Not Applicable	Unresectable Hepatocellular Carcinoma	110	TACE+PD-1 Inhibitors+Lenvatinib	(efjaprmzvf) = ihesmhewfb vbdaggjjrm (downkqlphe ) View more	Positive	21 Apr 2022
				TACE	(efjaprmzvf) = dgttafulwj vbdaggjjrm (downkqlphe ) View more
EASL_LCS2022	Not Applicable	Unresectable Intrahepatic Cholangiocarcinoma hepatitis B/C	32	TACE and lenvatinib	(ncinqampwn) = The occurrence of any-grade adverse events (AEs) was 81%. The most common AEs were decreased appetite (11 [34.3%]), hypertension (10 [31.2%]), and diarrhea (9[28.1%]) pdpefonbqh (gwhruwpakq )	Positive	03 Feb 2022
				TACE and lenvatinib plus PD-1 inhibitor
CSCO2021	Not Applicable	Liver Cancer	107	TACE+MWA联合治疗组	gsapauumpd(fvwduatkly) = whlzgvgwvk cmsbcwwobr (zoiuolcdtm ) View more	-	25 Sep 2021
				单纯TACE组	gsapauumpd(fvwduatkly) = rqckrzkvsw cmsbcwwobr (zoiuolcdtm ) View more